Tafalgie Therapeutics, a dynamic biotechnology and biopharmaceutical research company, has been named the winner of the prestigious European Innovation Council (EIC) Accelerator 2023. This recognition is testament to Tafagie Therapeutics’ groundbreaking work in non-opioid biologic drugs for pain relief.
Founded in 2020 as a spin-off from IBDM, Tafalgie Therapeutics has its roots in more than a decade of fundamental research carried out in Aziz Moqrich’s laboratory. The company specializes in the development of next-generation active drugs for the treatment of pain with no dependence or tolerance problems.
Congratulations to the whole Tafalgie team !
